Cian P. McCarthy, MB, BCh, BAO; Muthiah Vaduganathan, MD, MPH; James L. Januzzi Jr, MD
JAMA. 2018;320(5):433-434. doi:10.1001/jama.2018.7125
This Viewpoint reviews what is known about myocardial infarction (MI) caused by oxygen supply-and-demand mismatch (type 2 MI) and differences from MI caused by coronary artery disease, as well as proposes areas for further investigation to identify optimal management strategies.
Charlene A. Wong, MD, MSHP; Adrian F. Hernandez, MD, MHS; Robert M. Califf, MD
JAMA. 2018;320(5):435-436. doi:10.1001/jama.2018.7898
This Viewpoint encourages the development of approaches to share the results of research with study participants to reinforce the value of patient participation, to incentivize engagement in research, and to honor the belief that individuals have a right to their own data.
John A. Kellum, MD; Rinaldo Bellomo, MD; Claudio Ronco, MD
JAMA. 2018;320(5):437-438. doi:10.1001/jama.2018.7160
This Viewpoint discusses progress in the recognition and management of acute kidney injury (AKI) since publication in 2012 of KDIGO clinical practice guidelines to improve AKI outcomes, and proposes next steps in management, including use of biomarkers, risk alerts, and care bundles, to improve AKI prevention and outcomes.
Bernard Lo, MD; Deborah Grady, MD, MPH
JAMA. 2018;320(5):439-440. doi:10.1001/jama.2018.7625
This Viewpoint uses the case of an NIH trial funded by alcohol manufacturers and designed to determine the effects of moderate alcohol consumption on health outcomes to discuss the need for transparency in NIH-private partnerships and ways the NIH can administer those partnerships to preserve its integrity and trustworthiness.